用简约机器学习模型量化肺炎和脓毒症的免疫失调:多队列分析及氢化可的松随机对照试验再分析
该多队列分析基于35种血浆生物标志物,在398例社区获得性肺炎患者中构建免疫失调分期(DIP1-3)和连续评分(cDIP),并开发三生物标志物机器学习框架(降钙素原、可溶性TREM-1、IL-6)准确预测失调程度。该框架在五个外部队列(n=1191)中验证,且再分析CAPE COD试验显示氢化可的松仅在严重免疫失调患者中带来生存获益。
要点
- 临床严重程度不能充分代理免疫失调程度。
- 三生物标志物模型可准确预测35种标志物衍生的免疫失调分期和连续评分。
- 氢化可的松的生存获益仅限于模型判定的严重免疫失调患者。
核心结论
- 提供公开的三生物标志物框架可确定宿主反应失调程度,可能用于精准指导免疫调节治疗。
研究设计与样本
- 多队列分析及随机对照试验再分析,在三个独立队列的398例社区获得性肺炎患者中测量35种血浆生物标志物。
- 使用无监督轨迹推断分析识别免疫失调梯度,定义为离散分期(DIP)和连续评分(cDIP;0-1)。
- 开发两个简约机器学习模型基于35种生物标志物预测DIP分期和cDIP评分,并在五个独立队列(n=1191)中验证。
- 对评估氢化可的松治疗严重社区获得性肺炎的CAPE COD试验(NCT02517489)进行事后分析,评估不同DIP分期和cDIP连续范围内的治疗效果。
主要发现
- 基于35种血浆生物标志物将398例社区获得性肺炎患者沿免疫失调连续体从轻到重组织,产生三个失调分期(DIP1-3)和连续评分(cDIP)。
- 三生物标志物工具在五个外部队列中验证,涵盖不同感染、严重程度和护理环境(n=1191)。
临床怎么用
- 可使用三生物标志物(降钙素原、可溶性TREM-1、IL-6)框架量化免疫失调程度,辅助预后评估。
- 对于严重社区获得性肺炎患者,可考虑用DIP分期或cDIP评分识别可能从氢化可的松等免疫调节治疗中获益的严重免疫失调个体。
局限性
- 框架非为结局预测设计,但免疫失调与结局相关。
- 氢化可的松分析为事后分析,需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Sepsis is a dysregulated host response to infection resulting in life-threatening organ failure. Although immune dysregulation is central to the sepsis definition, immunomodulation trials enrol participants based on clinical severity, not the extent of dysregulation, which could contribute to treatment heterogeneity. A pragmatic way to quantify immune dysregulation could improve prognostication, help to evaluate treatment responses, and identify individuals most likely to benefit from immunomodulation. We aimed to construct a parsimonious machine-learning tool that defines and quantifies immune dysregulation, thereby supporting biologically informed immunomodulation. METHODS: In this multicohort analysis and reanalysis of a randomised controlled trial, the primary objective was to derive and validate a categorical and continuous immune dysregulation score that is independent of clinical presentation or outcome. We measured 35 plasma biomarkers reflecting key host response domains in individuals with community-acquired pneumonia (CAP) across different care settings (emergency department, general ward, and intensive care unit) and disease severities using data from three independent cohorts. We applied unsupervised trajectory inference analysis to identify an immune dysregulation gradient captured as discrete immune dysregulation stages (Dysregulated Immune Profile [DIP]) and a continuous score (cDIP; 0-1). We developed two parsimonious machine-learning models to predict the DIP stages and cDIP scores based on 35 biomarkers, and validated their ability to capture immune dysregulation and predict clinical outcomes in five independent cohorts. On the basis of our hypothesis that only individuals with severe immune dysregulation benefit from immunomodulation, we carried out a post-hoc analysis of a randomised trial evaluating hydrocortisone in severe CAP (CAPE COD trial, NCT02517489), assessing treatment effects across DIP stages and the cDIP continuum, and how hydrocortisone influenced dysregulation trajectories over time. FINDINGS: We organised 398 participants with CAP along a continuum of immune dysregulation from mild to severe on the basis of 35 plasma biomarkers, yielding three dysregulation stages (DIP1-3) and a continuous score (cDIP). Clinical severity proved to be an inadequate proxy for immune dysregulation. A three-biomarker machine-learning framework (procalcitonin, soluble TREM-1, and IL-6) accurately predicted the degree of dysregulation derived from 35 biomarkers (DIP stage accuracy 91·2%; cDIP root mean square error 0·056). Although the framework was not designed for outcome prediction, increased immune dysregulation-reflected in DIP and cDIP-was associated with a gradual rise in mortality (cDIP odds ratio [OR] 1·26 [95% CI 1·13-1·40] per 10% increase, p<0·0001) and secondary infections (OR 1·50 [1·22-1·93] per 10% increase, p=0·0005), independent of clinical severity. The three-biomarker tool was validated in five external cohorts of varying infections, severities, and care settings (n=1191). Reanalysis of the CAPE COD trial showed that hydrocortisone conferred a survival benefit only in participants classified as severely dysregulated by our model (30-day mortality: DIP3 OR 0·25 [0·05-0·85], p=0·042; cDIP ≥0·63 OR 0·21 [0·10-0·72], p=0·011), accompanied by faster immune recovery (time × treatment interaction, p<0·0001). No such effect modification was observed when stratifying participants by clinical severity. INTERPRETATION: We have provided a publicly available three-biomarker framework to determine the extent of host response dysregulation with potential value for precision-guided immunomodulatory therapy. FUNDING: EU Horizon 2020.
引用
- Michels, Dequin, Butler, et al. Quantifying immune dysregulation in pneumonia and sepsis with a parsimonious machine-learning model: a multicohort analysis across care settings and reanalysis of a hydrocortisone randomised controlled trial. Lancet Respir Med. 2026. PMID: 41856148. doi:10.1016/S2213-2600(25)00429-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。